FDA Panel Wants Heart Failure Risk on AstraZeneca Drugs

April 14, 2015 4:57 PM

53 0

Federal health advisers say labels on AstraZeneca's Onglyza and another related diabetes drug should carry new information about a possible association with heart failure and death.

The Food and Drug Administration's panel of diabetes experts voiced concern about data suggesting patients taking Onglyza and Kombiglize are at greater risk of hospitalization due to heart failure and dying. The panel voted 14-1 that that information should appear on the drugs' prescribing labeling....

Read more

To category page

Loading...